Literature DB >> 16452546

Systemic monocyte chemoattractant protein-1 concentrations are independent of type 2 diabetes or parameters of obesity: results from the Cooperative Health Research in the Region of Augsburg Survey S4 (KORA S4).

Christian Herder1, Sylvia Müller-Scholze, Philipp Rating, Wolfgang Koenig, Barbara Thorand, Burkhard Haastert, Rolf Holle, Thomas Illig, Wolfgang Rathmann, Jochen Seissler, H-Erich Wichmann, Hubert Kolb.   

Abstract

OBJECTIVE: Data on the relevance of monocyte chemoattractant protein (MCP)-1 in the pathophysiology of type 2 diabetes (T2D) and obesity are inconsistent. Since MCP-1 is produced by adipocytes and has been postulated to be involved in macrophage infiltration into adipose tissue, we wanted to test whether serum MCP-1 levels were correlated with T2D or obesity. DESIGN AND METHODS: Out of 1653 individuals aged 55 to 74 years participating in the population-based KORA Survey S4 (KORA/Cooperative Health Research in the Region of Augsburg) in Southern Germany, 236 patients with T2D, 242 subjects with impaired glucose tolerance and 244 normoglycaemic controls matched for age and sex were analysed for circulating MCP-1 concentrations.
RESULTS: MCP-1 serum concentrations were not associated with impaired glucose tolerance, type 2 diabetes or several parameters of obesity. Moreover, systemic MCP-1 levels were not significantly correlated with all but one (fasting triglycerides) of the biochemical markers tested.
CONCLUSIONS: Our data indicate that MCP-1 levels are not associated with T2D and that the contribution of fat mass to systemic MCP-1 protein might be low, suggesting that the possible local pathogenic role of MCP-1 may not be reflected by increased systemic levels of MCP-1.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16452546     DOI: 10.1530/eje.1.02090

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  10 in total

1.  Circulating levels of 8 cytokines and marine n-3 fatty acids and indices of obesity in Japanese, white, and Japanese American middle-aged men.

Authors:  Akira Sekikawa; Takashi Kadowaki; J David Curb; Rhobert W Evans; Hiroshi Maegawa; Robert D Abbott; Kim Sutton-Tyrrell; Tomonori Okamura; Chol Shin; Daniel Edmundowicz; Aya Kadota; Jina Choo; Aiman El-Saed; Hirotsugu Ueshima; Lewis H Kuller
Journal:  J Interferon Cytokine Res       Date:  2010-07       Impact factor: 2.607

2.  Chemokines as risk factors for type 2 diabetes: results from the MONICA/KORA Augsburg study, 1984-2002.

Authors:  C Herder; J Baumert; B Thorand; W Koenig; W de Jager; C Meisinger; T Illig; S Martin; H Kolb
Journal:  Diabetologia       Date:  2006-03-11       Impact factor: 10.122

3.  Proinflammatory cytokines in obesity: impact of type 2 diabetes mellitus and gastric bypass.

Authors:  Victoria Catalán; Javier Gómez-Ambrosi; Beatriz Ramirez; Fernando Rotellar; Carlos Pastor; Camilo Silva; Amaia Rodríguez; María J Gil; Javier A Cienfuegos; Gema Frühbeck
Journal:  Obes Surg       Date:  2007-11       Impact factor: 4.129

4.  Adipokines, inflammation, and visceral adiposity across the menopausal transition: a prospective study.

Authors:  Christine G Lee; Molly C Carr; Susan J Murdoch; Ellen Mitchell; Nancy F Woods; Mark H Wener; Wayne L Chandler; Edward J Boyko; John D Brunzell
Journal:  J Clin Endocrinol Metab       Date:  2009-01-06       Impact factor: 5.958

5.  Chemokines in Prediabetes and Type 2 Diabetes: A Meta-Analysis.

Authors:  Xiongfeng Pan; Atipatsa C Kaminga; Shi Wu Wen; Aizhong Liu
Journal:  Front Immunol       Date:  2021-05-13       Impact factor: 7.561

6.  Inflammatory adipokines, high molecular weight adiponectin, and insulin resistance: a population-based survey in prepubertal schoolchildren.

Authors:  Giuseppe Murdolo; Bettina Nowotny; Federica Celi; Miranda Donati; Vittorio Bini; Francesco Papi; Gabi Gornitzka; Serena Castellani; Michael Roden; Adriano Falorni; Christian Herder; Alberto Falorni
Journal:  PLoS One       Date:  2011-02-18       Impact factor: 3.240

7.  Neutralizing Anti-IL20 Antibody Treatment Significantly Modulates Low Grade Inflammation without Affecting HbA1c in Type 2 Diabetic db/db Mice.

Authors:  Christopher Mayer; Regine Bergholdt; Helena Cucak; Bidda Charlotte Rolin; Anette Sams; Alexander Rosendahl
Journal:  PLoS One       Date:  2015-07-10       Impact factor: 3.240

8.  Differential association of plasma monocyte chemoattractant protein-1 with systemic inflammatory and airway remodeling biomarkers in type-2 diabetic patients with and without asthma.

Authors:  Sardar Sindhu; Merin Koshy; Areej Abu Al-Roub; Nadeem Akhter; Saad Al Zanki; Shamsha Ali; Sriraman Devarajan; Rasheed Ahmad
Journal:  J Diabetes Metab Disord       Date:  2016-09-29

9.  Interdependencies among Selected Pro-Inflammatory Markers of Endothelial Dysfunction, C-Peptide, Anti-Inflammatory Interleukin-10 and Glucose Metabolism Disturbance in Obese Women.

Authors:  Joanna Janowska; Jerzy Chudek; Magdalena Olszanecka-Glinianowicz; Elżbieta Semik-Grabarczyk; Barbara Zahorska-Markiewicz
Journal:  Int J Med Sci       Date:  2016-06-25       Impact factor: 3.738

10.  Repetitive Intermittent Hyperglycemia Drives the M1 Polarization and Inflammatory Responses in THP-1 Macrophages Through the Mechanism Involving the TLR4-IRF5 Pathway.

Authors:  Fatema Al-Rashed; Sardar Sindhu; Hossein Arefanian; Ashraf Al Madhoun; Shihab Kochumon; Reeby Thomas; Sarah Al-Kandari; Abdulwahab Alghaith; Texy Jacob; Fahd Al-Mulla; Rasheed Ahmad
Journal:  Cells       Date:  2020-08-12       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.